| pubmed-article:12653924 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12653924 | lifeskim:mentions | umls-concept:C0026948 | lld:lifeskim |
| pubmed-article:12653924 | lifeskim:mentions | umls-concept:C0018563 | lld:lifeskim |
| pubmed-article:12653924 | lifeskim:mentions | umls-concept:C0765273 | lld:lifeskim |
| pubmed-article:12653924 | lifeskim:mentions | umls-concept:C0332237 | lld:lifeskim |
| pubmed-article:12653924 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:12653924 | lifeskim:mentions | umls-concept:C1522168 | lld:lifeskim |
| pubmed-article:12653924 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:12653924 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12653924 | pubmed:dateCreated | 2003-3-25 | lld:pubmed |
| pubmed-article:12653924 | pubmed:abstractText | Limited Stage IA mycosis fungoides (MF) is often treated with topical steroids, which can cause atrophy, or with nitrogen mustard, which imposes several limitations on the patient's lifestyle. Topical bexarotene is a novel synthetic rexinoid with few side-effects that has shown efficacy for treatment of mycosis fungoides skin lesions in recent Phase II-III clinical trials. The Phase I-II trial involving 67 stage IA-IIA MF patients demonstrated complete response (CR) in 21% and partial response (PR) in 42% of the patients. The median time to response was approximately 20 weeks. In the phase III trial of refractory stage IA, IB and IIA MF, the patients demonstrated a 44% response rate (8% CR). Patients with no prior therapy for mycosis fungoides responded at a higher rate (75%) than those with prior topical therapies. | lld:pubmed |
| pubmed-article:12653924 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12653924 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12653924 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12653924 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12653924 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12653924 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12653924 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12653924 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12653924 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12653924 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12653924 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:12653924 | pubmed:issn | 0011-9059 | lld:pubmed |
| pubmed-article:12653924 | pubmed:author | pubmed-author:MadyS MSM | lld:pubmed |
| pubmed-article:12653924 | pubmed:author | pubmed-author:DuvicMadelein... | lld:pubmed |
| pubmed-article:12653924 | pubmed:author | pubmed-author:TalpurRakhsha... | lld:pubmed |
| pubmed-article:12653924 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12653924 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:12653924 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12653924 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12653924 | pubmed:pagination | 238-41 | lld:pubmed |
| pubmed-article:12653924 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:meshHeading | pubmed-meshheading:12653924... | lld:pubmed |
| pubmed-article:12653924 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12653924 | pubmed:articleTitle | Long-term control of mycosis fungoides of the hands with topical bexarotene. | lld:pubmed |
| pubmed-article:12653924 | pubmed:affiliation | Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. | lld:pubmed |
| pubmed-article:12653924 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12653924 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12653924 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12653924 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:12653924 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:12653924 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12653924 | lld:pubmed |
